peg-interferon alfa-2a

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

35 competitors in Fibrosis

#DrugCompanyPhaseTrials

1

Actemra

Roche

Approved

12

Cellcept

Roche

Approved

13

Vemlidy

Gilead

Approved

14

Lexiscan

Astellas

Approved

15

Neoral

Novartis

Approved

16

Esbriet

LLegacy Health System

Approved

57

Rayos

RRoxane Laboratories

Approved

38

Glucophage

EMD Serono

Approved

39

Rapamune

PPrism Pharmaceuticals

Approved

210

Viagra

VViatris Specialty LLC

Approved

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Unknown status·PPusan National University Hospital·Phase 3·NCT01769833·144 enrolled

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Completed·Merck & Co.·Phase 3·NCT01544920·737 enrolled

Hepatitis C2 trials

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed·Bristol-Myers Squibb·Phase 3·NCT01471574·549 enrolled

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Completed·Bristol-Myers Squibb·Phase 3·NCT01389323·448 enrolled

Treatment1 trial

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Completed·Bristol-Myers Squibb·Phase 2·NCT01125189·558 enrolled

Skin Cancer1 trial

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Unknown status·UUniversity of California, San Diego·Phase 1/2·NCT00423397·16 enrolled

Thrombocytopenia1 trial

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Terminated·UUniversity of Southern California·Phase 2·NCT01153919·27 enrolled

7 more indications

Fibrosis1 trial

Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03957629·186 enrolled

Phase II1 trial

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Completed·Bristol-Myers Squibb·Phase 3·NCT01573351·398 enrolled

Breast Cancer1 trial

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00227656·2 enrolled

HBV1 trial

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

Completed·EEnyo Pharma·Phase 1·NCT03272009·73 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed·Roche·Phase 1·NCT02174172·158 enrolled

Plexiform Neurofibroma1 trial

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00253474·36 enrolled

Unspecified1 trial

Ph IIA Study (SOC +/- NS5B)

Completed·Bristol-Myers Squibb·Phase 2·NCT01193361·39 enrolled

Details

Drug Info

Related News